Novo Nordisk (NVO) stock pulled back early gain Friday after a report its oral Wegovy clocked 18,000 prescriptions in its second week on the market.
That absolutely demolished the 8,000 prescriptions that Eli Lilly's (LLY) injectable weight-loss drug, Zepbound, hit in its second week of launch. Evercore ISI analyst Umer Raffat notes the 18,000 number doesn't include online prescriptions through the company's direct-to-consumer website, NovoCare Pharmacy.
www.investors.com/news/technology/...-week-launch/?src=A00220